Compounds and use thereof in methods of treatment

Patent metadata

Field	Value
Publication number	US-12410116-B2
Application number	US-202318342312-A
Country	US
Kind code	B2
Filing date	Jun 27, 2023
Priority date	Dec 23, 2016
Publication date	Sep 9, 2025
Grant date	Sep 9, 2025

Abstract

Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.

First claim

The invention claimed is:

1. A method of treating a SOX7-, SOX17-, or SOX18-dependent cancer, comprising:
administering to a subject whose cancer has been tested for SOX7, SOX17, or SOX18 dependency an effective amount of a compound of Formula I:

wherein:
R 1 is selected from the group consisting of OH and OR 6 , wherein R 6 is C 1-4 alkyl;
R 2 is selected from the group consisting of H, COOR 7 , and C(O)NR 8 R 9 , wherein R 7 , R 8 , and R 9 are independently selected from the group consisting of H and C 1-4 alkyl;
R 3 is L-A, wherein L is a linker selected from the group consisting of C 2-8 alkyl, C 2-8 alkenyl, and C 2-8 alkoxyalkyl, and A is an optionally substituted naphthyl;
R 4 is selected from the group consisting of H, OR 10 , halo, and C 1-4 alkyl, wherein R 10 is selected from the group consisting of H and C 1-4 alkyl; and
R 5 is selected from the group consisting of H, OR 11 , halo, and C 1-4 alkyl, wherein R 11 is selected from the group consisting of H and C 1-4 alkyl;
or a pharmaceutically effective salt, solvate or prodrug thereof.

2. The method according to claim 1 , wherein the cancer is an angiogenesis and/or lymphangiogenesis related cancer.

3. The method according to claim 1 , wherein the cancer is selected from the group consisting of sarcomas, carcinomas, lymphomas, leukemias, and blastomas.

4. The method according to claim 3 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, lung cancer, bladder cancer, renal cancer, ovarian cancer, cervical cancer, uterine cancer, colon cancer, colorectal cancer, gastric cancer, head and neck cancer, liver cancer, kidney cancer, skin cancer, pancreatic cancer, pituitary cancer, musculoskeletal cancer, hemangioma, angioma, angiosarcoma, hepatoma, and hepatocellular carcinoma.

5. The method according to claim 1 wherein cancer metastasis is inhibited or prevented.

6. The method according to claim 1 wherein the compound of Formula I selectively inhibits SOX18-mediated transcription.

7. The method according to claim 1 wherein the compound of Formula I inhibits both DNA binding and transcription factor protein partner recruitment of SOX18.

8. The method according to claim 1 , wherein the compound of Formula I inhibits SOX18 homodimerization.

9. The method according to claim 1 , wherein the compound of Formula I inhibits SOX18-RBPJ heterodimerisation.

10. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is selected from the group consisting of OH and OR 6 wherein R 6 is C 1-4 alkyl;
R 2 is selected from the group consisting of H, COOR 7 , and C(O)NR 8 R 9 wherein R 7 , R 8 and R 9 are independently selected from H and C 1-4 alkyl;
R 3 is L-A wherein L is a linker selected from the group consisting of C 2-8 alkyl, C 2-8 alkenyl and C 2-8 alkoxyalkyl and A is an optionally substituted naphthyl, and wherein the substituted groups are selected from the group consisting of halo, C 1-4 alkyl, OC 1-4 alkyl, NH 2 , NH (C 1-4 alkyl), and N(C 1-4 alkyl) 2 ;
R 4 is selected from the group consisting of H, OR 10 , halo and C 1-4 alkyl wherein R 10 is selected from H and C 1-4 alkyl; and
R 5 is selected from the group consisting of H, OR 11 , halo and C 1-4 alkyl wherein R 11 is selected from H and C 1-4 alkyl.

11. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is selected from the group consisting of OH and OR 6 wherein R 6 is C 1-4 alkyl;
R 2 is selected from the group consisting of COOR 7 and C(O)NR 8 R 9 wherein R 7 , R 8 and R 9 are independently selected from the group consisting of H and C 1-4 alkyl;
R 3 is L-A wherein L is a linker selected from the group consisting of C 2-8 alkyl, C 2-8 alkenyl and C 2-8 alkoxyalkyl and A is an optionally substituted naphthyl;
R 4 is selected from the group consisting of H, OR 10 , halo and C 1-4 alkyl wherein R 10 is selected from the group consisting of H and C 1-4 alkyl; and
R 5 is H.

12. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is selected from the group consisting of OH and OR 6 wherein R 6 is C 1-4 alkyl;
R 2 is selected from the group consisting of H, COOR 7 , and C(O)NR 8 R 9 wherein R 7 , R 8 and R 9 are independently selected from the group consisting of H and C 1-4 alkyl;
R 3 is L-A wherein L is a linker selected from the group consisting of C 2-8 alkyl, C 2-8 alkenyl and C 2-8 alkoxyalkyl and A is selected from the group consisting of an unsubstituted naphthyl or a naphthyl substituted with one or more groups selected from the group consisting of halo, C 1-4 alkyl, OC 1-4 alkyl, NH 2 , NH (C 1-4 alkyl), and N(C 1-4 alkyl) 2 ;
R 4 is selected from the group consisting of H, OR 10 , halo and C 1-4 alkyl wherein R 10 is selected from the group consisting of H and C 1-4 alkyl; and
R 5 is selected from the group consisting of H, OR 11 , halo and C 1-4 alkyl wherein R 11 is selected from the group consisting of H and C 1-4 alkyl.

13. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is selected from the group consisting of OH and OR 6 wherein R 6 is C 1-4 alkyl;
R 2 is selected from the group consisting of COOR 7 and C(O)NR 8 R 9 wherein R 7 , R 8 and R 9 are independently selected from the group consisting of H and C 1-4 alkyl;
R 3 is L-A wherein L is a linker selected from the group consisting of C 2-8 alkyl, C 2-8 alkenyl and C 2-8 alkoxyalkyl and A is an optionally substituted naphthyl;
R 4 is H; and
R 5 is H.

14. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is OH;
R 2 is COOR 7 , wherein R 7 is selected from the group consisting of H and C 1-4 alkyl;
R 3 is L-A wherein L is a linker selected from the group consisting of C 2-8 alkyl, C 2-8 alkenyl and C 2-8 alkoxyalkyl and A is an optionally substituted naphthyl;
R 4 is H; and
R 5 is H.

15. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is OH;
R 2 is COOH;
R 3 is L-A wherein L is a linker selected from the group consisting of C 2-8 alkyl, C 2-8 alkenyl and C 2-8 alkoxyalkyl and A is an optionally substituted naphthyl;
R 4 is H; and
R 5 is H.

16. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is OH;
R 2 is COOH;
R 3 is L-A wherein L is C 2-8 alkyl and A is an optionally substituted naphthyl;
R 4 is H; and
R 5 is H.

17. The method according to claim 1 , wherein for the compound of Formula I:
R 1 is OH;
R 2 is COOH;
R 3 is L-A wherein L is C 2-8 alkyl and A is an unsubstituted naphthyl or a naphthyl substituted with one or more groups selected from the group consisting of halo, C 1-4 alkyl, OC 1-4 alkyl, NH 2 , NH (C 1-4 alkyl), and N(C 1-4 alkyl) 2 ;
R 4 is H; and
R 5 is H.

Assignees

• Univ Queensland

Inventors

• Francois Mathias
• Zuegg Johannes
• Overman Jeroen
• Mamidyala Sreeman Kumar
• Salim Angela Aguslyarti
• Fontaine Frank Roger
• Cooper Matthew Allister
• Capon Robert John
• Robertson Avril Alexis Barbara

Classifications

• A61K31/05

  Phenols {(cannabinoids A61K31/658)} · CPC title

• C07C233/65

  having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals · CPC title

• C07C63/331

  with all carboxyl groups bound to non-condensed rings · CPC title

• C07C43/215

  having unsaturation outside the six-membered aromatic rings · CPC title

• C07C39/15

  with all hydroxy groups on non-condensed rings {, e.g. phenylphenol} · CPC title